Clinical Trials · NCT05199038

Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study

Name: Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownPhase 4Octreotide

Phase: Phase 4
Recruitment status: Unknown
Sponsor: Tanta University
Enrollment: 184
Start date: Jun 2022
Locations: See registry
Primary endpoint: Esophageal varices rebleed within 5days after control of initial bleed

View Octreotide compound reference